A detailed history of Morgan Stanley transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 220,248 shares of FLGT stock, worth $4.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
220,248
Previous 263,286 16.35%
Holding current value
$4.55 Million
Previous $7.61 Million 37.21%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$21.55 - $29.29 $927,468 - $1.26 Million
-43,038 Reduced 16.35%
220,248 $4.78 Million
Q4 2023

Feb 13, 2024

BUY
$23.64 - $30.27 $305,641 - $391,360
12,929 Added 5.16%
263,286 $7.61 Million
Q3 2023

Nov 15, 2023

BUY
$26.74 - $40.81 $795,488 - $1.21 Million
29,749 Added 13.49%
250,357 $6.69 Million
Q2 2023

Aug 14, 2023

SELL
$28.52 - $40.7 $2.35 Million - $3.35 Million
-82,299 Reduced 27.17%
220,608 $8.17 Million
Q1 2023

May 15, 2023

BUY
$29.39 - $36.27 $1.14 Million - $1.41 Million
38,819 Added 14.7%
302,907 $9.46 Million
Q4 2022

Feb 14, 2023

SELL
$29.23 - $40.28 $736,566 - $1.02 Million
-25,199 Reduced 8.71%
264,088 $7.86 Million
Q3 2022

Nov 14, 2022

BUY
$37.92 - $63.74 $1.79 Million - $3.01 Million
47,227 Added 19.51%
289,287 $11 Million
Q2 2022

Oct 27, 2022

BUY
$47.98 - $62.75 $1.36 Million - $1.77 Million
28,270 Added 13.22%
242,060 $13.2 Million
Q2 2022

Aug 15, 2022

BUY
$47.98 - $62.75 $1.36 Million - $1.77 Million
28,270 Added 13.22%
242,060 $13.2 Million
Q1 2022

Oct 27, 2022

SELL
$49.85 - $96.11 $1.41 Million - $2.72 Million
-28,270 Reduced 11.68%
213,790 $13.3 Million
Q1 2022

May 13, 2022

BUY
$49.85 - $96.11 $1.86 Million - $3.58 Million
37,266 Added 21.11%
213,790 $13.3 Million
Q4 2021

Feb 14, 2022

BUY
$77.3 - $105.0 $996,319 - $1.35 Million
12,889 Added 7.88%
176,524 $17.8 Million
Q3 2021

Nov 15, 2021

BUY
$74.87 - $110.87 $12.3 Million - $18.1 Million
163,635 New
163,635 $14.7 Million

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $625M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.